Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.

Autor: Tiribelli M; Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.; Department of Medical Area, University of Udine, Udine, Italy., Toffoletti E; Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.; Department of Medical Area, University of Udine, Udine, Italy., Di Giusto S; Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy., Fanin R; Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.; Department of Medical Area, University of Udine, Udine, Italy., Damiani D; Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.; Department of Medical Area, University of Udine, Udine, Italy.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2023 Mar; Vol. 110 (3), pp. 330-331. Date of Electronic Publication: 2022 Dec 13.
DOI: 10.1111/ejh.13907
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje